Eternal Peptides

Overview

Eternal Peptides is a US-based vendor that has emerged alongside Peptide Partners as one of the top-testing vendors in the Finnrick Analytics database. With 23 independently tested samples across 5 products and ratings ranging from A to B, the company positions itself around longevity and anti-aging compounds with a strong emphasis on lab-verified quality.

What We Found

Testing & Quality (Score: 75/100)

Finnrick Analytics data paints a consistently positive picture:

• BPC-157: Finnrick A (“Great”) — 7 samples tested (May–Nov 2025), confident rating with scores averaging above 7.0
• Semaglutide: Finnrick B (“Good”) — 4 samples tested (May 2025), tentative rating
• Tirzepatide: Finnrick B (“Good”) — 4 samples tested (May 2025), tentative rating
• Retatrutide: Finnrick B (“Good”) — 4 samples tested (May 2025), tentative rating
• 23 total samples across 5 products

The BPC-157 A rating matches the top tier (alongside Peptide Sciences and Peptide Partners). The B ratings on GLP-1 compounds are solid. The “tentative” designation on semaglutide, tirzepatide, and retatrutide reflects sample size (4 each) rather than quality concerns — scores were consistently above thresholds.

The company maintains a public lab tests page on their website, which is a significant transparency positive.

Transparency (Score: 65/100)

Public lab test archive available on website. Finnrick partnership provides independent verification. The longevity/anti-aging brand positioning is clear. Specific manufacturing details and lab partners are less prominently disclosed, though testing data partially compensates.

Pricing (Score: 55/100)

Premium pricing consistent with vendors investing in comprehensive testing programs. The testing overhead represents real costs that budget vendors avoid.

Reputation (Score: 55/100)

Relatively new vendor with limited review history outside of Finnrick data. No Trustpilot or BBB presence identified. The Finnrick ratings serve as the primary reputation signal. No controversies or complaints identified, though limited history means limited data points.

Compliance (Score: 55/100)

Standard research-use disclaimers. Sells GLP-1 compounds (semaglutide, tirzepatide, retatrutide) which are under active FDA enforcement scrutiny — this represents elevated regulatory risk for both vendor and buyers. No known enforcement actions.

The PeptideExaminer Verdict

Eternal Peptides delivers strong independent testing results across multiple product categories, with the BPC-157 A rating placing it in the top tier. The breadth of Finnrick testing (5 products vs. single-product testing at many competitors) provides broader confidence. The B ratings on GLP-1 compounds are notable since these are high-value, high-risk products frequently counterfeited. Limited reputation history is the main constraint — more time and more customer feedback will clarify whether operational quality matches testing quality.

Grade: B

Category	Score	Weight	Weighted
Transparency	65	20%	13.0
Testing	75	25%	18.75
Pricing	55	15%	8.25
Reputation	55	20%	11.0
Compliance	55	20%	11.0
Total			62.0 → B

Sources: Finnrick Analytics (finnrick.com, 23 samples), eternalpeptides.com